Comparison of treatment-related adverse events of different Cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer: A network meta-analysis

医学 帕博西利布 富维斯特朗 耐受性 转移性乳腺癌 中止 不利影响 肿瘤科 乳腺癌 中性粒细胞减少症 内科学 危险系数 药理学 癌症 化疗 雌激素受体 置信区间
作者
Alexandra Desnoyers,Michelle B. Nadler,Vikaash Kumar,Ramy Saleh,Eitan Amir
出处
期刊:Cancer Treatment Reviews [Elsevier BV]
卷期号:90: 102086-102086 被引量:51
标识
DOI:10.1016/j.ctrv.2020.102086
摘要

Abstract

Background

Palbociclib, ribociclib and abemaciclib have all been approved in combination with endocrine therapy in hormone-receptor positive, HER2 negative metastatic breast cancer. While the efficacy of these drugs appears similar, differences in safety and tolerability are apparent.

Methods

We searched PubMed and ASCO, ESMO and SABCS proceedings to identify randomized trials of palbociclib, ribociclib and abemaciclib. Data on common and serious adverse events (AE) were extracted for each approved drug. The odds ratio for each AE and the hazard ratio for progression-free survival were calculated relative to endocrine therapy alone. A network meta-analysis was then performed for each endocrine therapy backbone (aromatase inhibitor (AI) or fulvestrant) to compare ribociclib and abemaciclib to palbociclib.

Results

8 trials were included in the analysis and comprised 2799 patients receiving cyclin-dependent kinase 4/6 inhibitors palbociclib: 873 patients; ribociclib: 1153 patients; abemaciclib: 773 patients. In 5 trials (1524 patients), the endocrine therapy backbone was an AI and in 3 trials (1275 patients) it was fulvestrant. Compared to palbociclib, ribociclib and abemaciclib showed significantly lower grade 3–4 neutropenia, but significantly higher GI toxicity. Treatment discontinuation was higher with abemaciclib than other drugs. Efficacy of the 3 drugs was similar. Compared to palbociclib, for AI backbone, the HR for PFS for ribociclib was 0.98 and for abemaciclib 1.02. For fulvestrant backbone, the HR were 0.88 and 0.93 respectively.

Conclusions

Palbociclib, ribociclib and abemaciclib have comparable efficacy, but differences in safety and tolerability. Abemaciclib has worse tolerability with significantly higher treatment discontinuation likely due to GI toxicity.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
Orange的应助被他说采纳,获得10
刚刚
唐萧发布了新的文献求助10
1秒前
鲸落小小的应助被科研答辩采纳,获得10
1秒前
JSzzZ完成签到,获得积分10
1秒前
1秒前
大胆的幻巧完成签到,获得积分10
3秒前
hgq完成签到,获得积分10
3秒前
顺利初之完成签到,获得积分10
3秒前
HTT发布了新的文献求助10
3秒前
铃铛完成签到 ,获得积分10
4秒前
专注乐荷完成签到,获得积分10
4秒前
锦李完成签到,获得积分10
4秒前
4秒前
4秒前
wyd222完成签到,获得积分10
4秒前
4秒前
饱满的睫毛膏完成签到,获得积分10
5秒前
5秒前
zoe11完成签到,获得积分10
5秒前
JKfeng完成签到,获得积分10
5秒前
不会取名啊完成签到,获得积分10
5秒前
333发布了新的文献求助10
5秒前
腼腆的尔芙完成签到 ,获得积分10
6秒前
ygm完成签到,获得积分10
6秒前
yhwang_smu发布了新的文献求助10
7秒前
superZ完成签到,获得积分10
7秒前
郭天浩完成签到,获得积分10
7秒前
8秒前
李星云完成签到,获得积分10
8秒前
8秒前
HaohaoLi完成签到,获得积分10
9秒前
minkeyantong完成签到 ,获得积分10
9秒前
只只完成签到,获得积分10
9秒前
ZZU1997发布了新的文献求助10
9秒前
9秒前
YY发布了新的文献求助10
9秒前
研友_24789完成签到,获得积分10
9秒前
Janmy完成签到,获得积分10
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180488
求助须知:如何正确求助?哪些是违规求助? 9570485
关于积分的说明 21812623
捐赠科研通 7776592
什么是DOI,文献DOI怎么找? 3433286
关于科研通互助平台的介绍 2557522
邀请新用户注册赠送积分活动 2479162